Targeting eCyPA-CD147 Binding for Multiple Myeloma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating multiple myeloma and related hematological malignancies are inadequate in addressing the migration and proliferation of cancer cells to the bone marrow, as well as in diagnosing and monitoring the progression of the disease.
Innovation Solution
The use of extracellular cyclophilin A (eCyPA) and its receptor CD147 as therapeutic targets, involving methods to disrupt their binding and develop agents that inhibit their interaction, along with assays to determine eCyPA levels for prognosis and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used for multiple myeloma, then general cancer treatment is provided, but migration and proliferation of cancer cells to the bone marrow is not effectively addressed
Solution Approach 1:
The patent uses the eCyPA-CD147 binding interaction as a mediator to specifically target multiple myeloma cells in the bone marrow microenvironment. By disrupting this intermediary binding with test agents, the treatment addresses the specific mechanism of MM cell migration and proliferation without affecting other cancer types or normal cells.
Solution Approach 2:
The patent changes the therapeutic parameter from general cancer treatment to specifically targeting the eCyPA-CD147 binding interaction. This parameter change enables selective inhibition of MM cell migration and proliferation by measuring binding disruption as a therapeutic endpoint.
2Reliability
If eCyPA and CD147 binding disruption is used as a therapeutic strategy, then migration and proliferation of multiple myeloma cells is inhibited, but new therapeutic agents must be developed and screened
Solution Approach 1:
The patent employs a self-service screening system where the eCyPA-CD147 binding assay automatically identifies therapeutic agents. The binding disruption measurement serves as both the target mechanism and the screening criterion, eliminating the need for separate efficacy studies and streamlining agent development.
Solution Approach 2:
The patent replaces complex in vivo efficacy testing with a simplified in vitro binding disruption assay. By substituting the mechanical/biological complexity of tracking cell migration and proliferation with a direct binding measurement, the screening process becomes more efficient and manufacturable.
3Ease of operation
If eCyPA levels are measured for diagnosis and prognosis, then non-invasive diagnostic tools are provided, but assay development and standardization are required
Solution Approach 1:
The patent creates a universal eCyPA measurement assay that serves multiple functions: diagnosis of multiple myeloma, prognosis assessment, and monitoring of treatment response. This multi-functionality reduces the need for separate diagnostic tools and simplifies clinical workflow despite the complexity of assay standardization.
4Measurement precision
If binding disruption assays are used to identify therapeutic agents, then specific agents for multiple myeloma can be found, but the screening process requires complex binding measurements
Solution Approach 1:
The patent extracts the eCyPA-CD147 binding interaction from the complex cellular environment and isolates it for direct measurement. By taking out this specific binding event and measuring it in isolation, the assay achieves high precision in identifying therapeutic agents without requiring complex cellular or organismal systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively inhibits the migration and proliferation of multiple myeloma cells to the bone marrow, provides non-invasive diagnostic and prognostic tools, and monitors treatment effectiveness by assessing eCyPA levels, offering a novel strategy for managing multiple myeloma and related conditions.
Implementation Method 1
providing a first polypeptide comprising a CD147 polypeptide and a second polypeptide comprising an extracellular cyclophilin A (eCyPA) polypeptide sequence under conditions that allow for binding of the CD147 polypeptide and the eCyPA sequence
Data Source
AI summary
Provided by the invention are methods for identifying therapeutic agents for treating multiple myeloma or another hematological malignancy, as well as methods for determining the prognosis of a patient with multiple myeloma or another hematological malignancy. The methods are based in part on the inventors' discovery that an extracellular form of cyclophilin A binds to CD147 expressed on multiple myeloma cells.